2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

• Status: Not yet recruiting
• Trial end date: 2023-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt University Medical Center
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)

Criteria

Inclusion Criteria:

• Individuals with heterozygous Familial Hypercholesterolemia.

Exclusion Criteria:

• Myocardial infarction or stroke within the last 6 months

• unstable angina, symptoms of angina within the last 3 months

• NYHA class III or IV heart failure or LVEF < 30%

• poorly controlled hypertension: SBP > 180 mm Hg or DBP > 110 mm Hg,

• pregnancy,

• evidence of a previous acute coronary syndrome,

• current smokers,

• individuals with Type 2 Diabetes Mellitus, obesity (BMI > 30),

• hypertriglyceridemia (fasting TG > 250 mg/dl),

• renal insufficiency (Cr > 1.8),

• hepatic disease (aspartate aminotransferase(AST) or alanine aminotransferase (ALT) > 2x ULN),

• hypothyroidism,

• nephrotic syndrome,

• rheumatoid arthritis,

• systemic lupus erythematosus,

• AIDS or HIV

• history of malignancy of any organ in last 5 years.